ARTICLE | Clinical News

MorphoSys preclinical data

May 30, 2011 7:00 AM UTC

In a mouse model of MM, 12 mg/kg MOR202 reduced tumor-mediated bone destruction by 55% compared to vehicle-treated controls. Furthermore, 3 mg/kg MOR202 plus lenalidomide or bortezomib completely abolished tumor-mediated bone destruction. Data will be presented at the American Society of Clinical Oncology meeting in Chicago in June. MorphoSys plans to start a Phase I/IIa trial of the human antibody against CD38 this half. ...